When was Relation founded?

Relation was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Relation located?

Relation is headquartered in London, United Kingdom. It is registered at 6TH FLOOR,ONE LONDON WALL,LONDON,UNITED KINGDOM,EC2Y 5EB.

How many employees does Relation have?

As of Aug 31, 2026, the latest employee count at Relation is 142.

Is Relation a funded company?

Relation is a funded company, having raised a total of $116M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 10, 2021.

When was the latest funding round of Relation?

Relation's latest funding was a $***** Seed round on Nov 21, 2025, with participation from 3 investors.

Where does Relation rank among its competitors?

Relation ranks 25th amongst 679 active competitors, of which 249 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Relation, which secured $36.2M in Nov, 2025.

Who are the top competitors of Relation?

Relation's top competitors include Alnylam, Spark Therapeutics and DNAnexus. Among them, Relation secured the most recent funding round in November, 2025.

Relation - 2026 Company Profile, Team, Funding, Competitors & Financials

Relation is a seed company based in London (United Kingdom), founded in 2019 by Charles Roberts and Benjamin Swerner. It operates as an AI-based drug development tools for researchers. Relation has raised $116M in funding from DCVC and Magnetic Ventures. The company has 679 active competitors, including 249 funded and 136 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and DNAnexus.

Company Details

AI-based drug development tools for researchers. The company has developed software for target and drug discovery. The platform leverages human genetics, single-cell omics, and perturbational data for genetic disease management.

Website: www.relationrx.com/
Social
Email ID: *****@relationrx.com
Registered Address: 6TH FLOOR,ONE LONDON WALL,LONDON,UNITED KINGDOM,EC2Y 5EB

Key Metrics

Founded Year

2019

Location

London, United Kingdom

Stage

Seed

Total Funding

$116M in 5 rounds

Latest Funding Round

Seed, Nov 21, 2025, $*****

Investors

DCVC & 10 more

Ranked

25^th among 679 active competitors

Employee Count

142 as on Aug 31, 2026

Similar Companies

Alnylam & 3651 more

View Relation's full profile

Relation is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
RELATION THERAPEUTICS LIMITED CIN: 12305953 , United Kingdom, Active	Nov 07, 2019	-	-
Relation Therapeutics Ltd CIN: 12305953 , United Kingdom, Active	Nov 07, 2019	-	6 (As on Nov 30, 2020)

Relation has raised a total funding of $116M over 5 rounds. Its first funding round was on Aug 10, 2021. Its latest funding round was a Seed round on Nov 21, 2025 for $*****. 3 investors participated in its latest round. Relation has 10 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Relation:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 21, 2025	9566951	Seed	3538929	9616461	6358528	8909792
Nov 22, 2024	2504166	Seed	3131393	3873315	7202324	GSK
Jan 09, 2024	3342502	Seed	2609124	2523259	DCVC	Magnetic Ventures & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Relation's funding rounds and investors

The founders of Relation are Charles Roberts and Benjamin Swerner. David Roblin is the CEO of Relation.

Here are the details of Relation's key team members:

Charles Roberts: Co-Founder of Relation and founder of 1 other company. They are also an angel investor in 1 startup.
Benjamin Swerner: Co-Founder & COO of Relation.
David Roblin: CEO of Relation.
Contact Info: 1 email address

View details of Relation's Founder profiles and Board Members

Relation's employee count trend

Relation has 142 employees as of Aug 26. Here is Relation's employee count trend over the years:

Uncover Relation's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Relation include Alnylam, Spark Therapeutics and DNAnexus. Here is the list of Top 10 competitors of Relation, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
3rd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	71/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Fidelity Investments & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100
25th	Relation 2019, London (United Kingdom), Seed	AI-based drug development tools for researchers	$116M	ARK Investment Management, Deerfield & 9 others	64/100